AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04934579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
Study NCT04934579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
Study NCT04934579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Study NCT03720938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Video Games
Description: Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
Study NCT01155154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalexin
Description: 500 mg (two 250 mg capsules) every 6 hours for 7 days
Study NCT01155154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin
Description: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
Study NCT01155154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two placebo capsules every 6 hours for 7 days
Study NCT01152346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine for Injection
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
Study NCT02320292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02320292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02320292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT02320292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02320292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y-90 Ibritumomab Tiuxetan
Description: Given IV
Study NCT01152346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vidaza®
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
Study NCT01256164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibrocaps (fibrin sealant)
Description: Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
Study NCT01256164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam
Description: An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
Study NCT00199238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rupatadine Fumarate
Study NCT00199238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine Fumarate
Study NCT05742828 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Seating Coach
Description: Power wheelchair intervention
Study NCT04437433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg
Description: Tablets containing 60 mg atogepant
Study NCT02470494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound amplification provided via the EarLens CHD
Description: Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
Study NCT00904761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
Study NCT02177916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Study NCT02710812 — intervention group
Intervention type: PROCEDURE
Intervention: Local Excision or Wait-and-See
Description: Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).~The following principles should be respected:~1. A gross margin of at least 0.5 cm;~2. full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;~3. determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist.
Study NCT02915848 — intervention group
Intervention type: DEVICE
Intervention: PC+S group
Description: PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
Study NCT01756911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MFM
Description: Implantation of the MFM
Study NCT01497522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin 50 mg twice daily
Study NCT01497522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo of vildagliptin 50 mg twice daily
Study NCT03072940 — intervention group
Intervention type: OTHER
Intervention: Clinical investigations
Description: Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
Study NCT02522143 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Informational sessions describing BPD characteristics
Description: Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
Study NCT02522143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed-DBT treatment intervention
Description: The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
Study NCT02521662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: A transdermal patch that slowly releases nicotine into the body through the skin.
Study NCT02521662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
Study NCT04551274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
Study NCT05938764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MICRA
Description: see earlier description
Study NCT05938764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: see earlier description
Study NCT03324555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Oral suspension
Study NCT02521662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine contained in e-liquid (e-juice) used in e-cigarettes
Study NCT02521662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural support
Description: Withdrawal-oriented behavioural support
Study NCT01058304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Physical Therapy for Knee OA
Description: The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
Study NCT01058304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Physical Therapy for Knee OA
Description: The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
Study NCT03882879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Karate Classes
Description: Eligible subjects will engage in twice-weekly karate classes for 6 months, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief
Study NCT03882879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Intervention Study Visit
Description: At the pre-intervention study visit, the study logistics will be reviewed, informed consent process will occur, the subject will complete a battery of pre-intervention assessments focused on overall mobility, gait, balance, mood, cognition, and quality of life, and the subjects will be prompted to share their expectations of and goals for the karate classes.
Study NCT03882879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimonthly Online Survey
Description: All participants in both arms will receive a personalized email every two months directing them to indicate how frequently they have attended karate classes, how frequently they have engaged in exercise, how frequently they have fallen, whether their PD medication regimen has changed, and they will complete brief surveys about mood, camaraderie, and overall quality of life.
Study NCT03882879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-month Study Visit
Description: All participants in both arms will complete questionnaires and assessments of their PD symptoms, cognition, mood, camaraderie, and quality of life. Subjects will meet with a member of the study team to complete a series of physical and cognitive assessments. At this visit, subjects will review the initial expectations they shared at the pre-intervention visit and indicate if they thought their goals were achieved for the class.
Study NCT03882879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-month Study Visit
Description: At the 12-month study visit, the assessments from the baseline and 6-month study visit will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
Study NCT00901108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabectome-IOL
Description: Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery.
Study NCT01069354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse® Injectable Dermal Filler with Lidocaine
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
Study NCT01069354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse® Injectable Dermal Filler without Lidocaine
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
Study NCT02392325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1Δ30
Description: Administered subcutaneously in 0.5 mL containing 10\^3.0 plaque-forming units (PFU)
Study NCT02392325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously in 0.5 mL
Study NCT02392325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169
Description: Administered subcutaneously in 0.5 mL containing 10\^3.0 PFU
Study NCT01281202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin
Description: Tablets
Study NCT01281202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Tablets
Study NCT03346811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
Study NCT03536286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encouragement
Description: Households will be visited and encouraged to enroll in Asili
Study NCT00521703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
Study NCT00521703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tannic acid
Description: oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
Study NCT01494428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/allograft bone dowel
Description: The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
Study NCT01494428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/allograft bone dowel
Description: An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
Study NCT03172702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Cyclosilicate
Description: Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
Study NCT03118921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
Study NCT01077544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water.
Study NCT03320616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral EYP001a capsules - 100 mg strength
Study NCT00901108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trab-IOL
Description: Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C.
Study NCT04026529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking on incline or walking at increasing speed
Description: Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~Subjects will be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 \& 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or slope.
Study NCT04723823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor or sensory imagery with fMRI
Description: Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
Study NCT03574597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
Study NCT03574597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
Study NCT02770781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Subjects will receive a personal exercise regimen based on their health history and individual capability.
Study NCT04237506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted ballet dance
Description: The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
Study NCT01868295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleeping with denture
Description: Sleeping with denture at night
Study NCT01011621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% prednisolone acetate cream
Description: Small amount applied over the lesion twice a day for 14 days.
Study NCT01637922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 201335
Description: BI 201335 for 9 days
Study NCT01011621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Description: Small amount applied over the lesion twice a day for 14 days.
Study NCT01071564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT01071564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01071564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT01071564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01071564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT00528489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PennVax B
Description: DNA vaccine containing the HIV genes Gag, Pol, and Env
Study NCT05313178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bacillus Coagulans GBI-30, 6086
Description: In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.